$248.5 million is the oddest number in AnaptysBio's latest filing. Cash rose 126.2% from the comparable balance, even as three-month revenue fell 66.5% to $25.6 million and operating cash flow stayed negative at $25.9 million.
That makes the filing look, at first glance, like a cash-rich biotech with a sharply lower-revenue period. The more useful reading is narrower: the balance sheet got fuller, but the operating engine did not suddenly start funding itself.
AnaptysBio's financing footnote shows $14.0 million of cash from issuing common stock, offset by $12.8 million of repayments tied to the sale of future royalties. Financing activities therefore provided $1.2 million during the three months. The company does not disclose in these receipts what drove the rest of the cash increase from $109.8 million to $248.5 million.
"Financing Activities Net cash provided by financing activities during the three months ended March 31, 2026 of $1.2 million was primarily due to $14.0 million of cash received for the issuance of common stock, offset by $12.8 million for principal repayments of the liability for the sale of future royalties."
AnaptysBio, 10-Q, May 12, 2026
That is a balance-sheet receipt, not an operating turnaround. The income statement moved from $15.1 million of net income to a $52.9 million net loss, while operating margin swung from 45.5% to negative 135.5%.
Some of the pipeline spending actually declined. Research and development expense fell to $34.0 million, mainly because clinical expense dropped by $7.8 million. The loss coincided with higher general and administrative costs tied to legal work and stock compensation.
"The increase is primarily due to an $8.3 million increase in legal expenses due to the GSK lawsuit and activity related to the separation of the business, a $4.9 million increase in stock compensation expense, a $0.7 million increase in personnel costs, and a $0.8 million net increase in other general and administrative expenses, offset by a $2.5 million decrease in transaction costs related to our Vanda License Agreement, and a $0.1 million decrease in market research costs."
AnaptysBio, 10-Q, May 12, 2026
The filing puts the operating tension in plain numbers: less clinical spending, sharply less revenue, and a much larger loss after legal and separation-related costs. Stock compensation also rose 55.3% year over year, an accounting expense rather than a cash payment, but one that still affects reported profitability and dilution economics.
The Vanda relationship is part of the licensing backdrop around the revenue line. AnaptysBio granted Vanda an exclusive global license for imsidolimab in January 2025, after the drug completed two registration-enabling Phase 3 trials. That is a commercial milestone, but it does not turn a single period's license or royalty economics into recurring operating revenue.
AnaptysBio's annual results show how lumpy that backdrop can be: revenue reached $234.6 million in 2025 after rising 157.0%, while the latest three-month period gave back much of that momentum. Its shares closed at $55.20 on September 18, up 0.4% that day, after a 152.0% gain over the prior year.
The unanswered question is simple: what specifically turned $109.8 million of cash into $248.5 million while operating cash flow remained negative?